JP2015519404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519404A5 JP2015519404A5 JP2015517469A JP2015517469A JP2015519404A5 JP 2015519404 A5 JP2015519404 A5 JP 2015519404A5 JP 2015517469 A JP2015517469 A JP 2015517469A JP 2015517469 A JP2015517469 A JP 2015517469A JP 2015519404 A5 JP2015519404 A5 JP 2015519404A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- dnc
- cyclobenzaprine
- composition
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 169
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 151
- 229960003572 cyclobenzaprine Drugs 0.000 claims description 151
- 238000000034 method Methods 0.000 claims description 89
- 238000010521 absorption reaction Methods 0.000 claims description 82
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 81
- 229960000836 amitriptyline Drugs 0.000 claims description 81
- 230000036470 plasma concentration Effects 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000002610 basifying agent Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- UZLGHNUASUZUOR-UHFFFAOYSA-L dipotassium;3-carboxy-3-hydroxypentanedioate Chemical compound [K+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UZLGHNUASUZUOR-UHFFFAOYSA-L 0.000 claims description 3
- 239000002526 disodium citrate Substances 0.000 claims description 3
- 235000019262 disodium citrate Nutrition 0.000 claims description 3
- -1 disodium hydrogen Chemical class 0.000 claims description 3
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical group [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006190 sub-lingual tablet Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 235000015870 tripotassium citrate Nutrition 0.000 claims description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 235000019263 trisodium citrate Nutrition 0.000 claims description 3
- 229940038773 trisodium citrate Drugs 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 3
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 239000007935 oral tablet Substances 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660593P | 2012-06-15 | 2012-06-15 | |
| US61/660,593 | 2012-06-15 | ||
| US201261667774P | 2012-07-03 | 2012-07-03 | |
| US61/667,774 | 2012-07-03 | ||
| US201261725402P | 2012-11-12 | 2012-11-12 | |
| US61/725,402 | 2012-11-12 | ||
| US201361792900P | 2013-03-15 | 2013-03-15 | |
| US61/792,900 | 2013-03-15 | ||
| PCT/US2013/046023 WO2013188847A1 (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017192713A Division JP2017222726A (ja) | 2012-06-15 | 2017-10-02 | 経粘膜吸収のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519404A JP2015519404A (ja) | 2015-07-09 |
| JP2015519404A5 true JP2015519404A5 (enExample) | 2016-07-28 |
| JP6259452B2 JP6259452B2 (ja) | 2018-01-10 |
Family
ID=49758769
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517469A Active JP6259452B2 (ja) | 2012-06-15 | 2013-06-14 | 経粘膜吸収のための組成物および方法 |
| JP2017192713A Withdrawn JP2017222726A (ja) | 2012-06-15 | 2017-10-02 | 経粘膜吸収のための組成物および方法 |
| JP2019091262A Withdrawn JP2019123757A (ja) | 2012-06-15 | 2019-05-14 | 経粘膜吸収のための組成物および方法 |
| JP2021100154A Withdrawn JP2021138765A (ja) | 2012-06-15 | 2021-06-16 | 経粘膜吸収のための組成物および方法 |
| JP2024014696A Pending JP2024032964A (ja) | 2012-06-15 | 2024-02-02 | 経粘膜吸収のための組成物および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017192713A Withdrawn JP2017222726A (ja) | 2012-06-15 | 2017-10-02 | 経粘膜吸収のための組成物および方法 |
| JP2019091262A Withdrawn JP2019123757A (ja) | 2012-06-15 | 2019-05-14 | 経粘膜吸収のための組成物および方法 |
| JP2021100154A Withdrawn JP2021138765A (ja) | 2012-06-15 | 2021-06-16 | 経粘膜吸収のための組成物および方法 |
| JP2024014696A Pending JP2024032964A (ja) | 2012-06-15 | 2024-02-02 | 経粘膜吸収のための組成物および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140171515A1 (enExample) |
| EP (1) | EP2861223B1 (enExample) |
| JP (5) | JP6259452B2 (enExample) |
| CN (2) | CN111388430A (enExample) |
| AR (1) | AR092330A1 (enExample) |
| AU (2) | AU2013274003B2 (enExample) |
| BR (1) | BR112014031394B1 (enExample) |
| CA (2) | CA3118913C (enExample) |
| DK (1) | DK2861223T3 (enExample) |
| ES (1) | ES2929133T3 (enExample) |
| HR (1) | HRP20221325T1 (enExample) |
| HU (1) | HUE060175T2 (enExample) |
| IL (1) | IL236268B (enExample) |
| LT (1) | LT2861223T (enExample) |
| MX (2) | MX382516B (enExample) |
| MY (1) | MY194495A (enExample) |
| NZ (2) | NZ631144A (enExample) |
| PL (1) | PL2861223T3 (enExample) |
| PT (1) | PT2861223T (enExample) |
| RS (1) | RS63822B1 (enExample) |
| SG (2) | SG11201408318RA (enExample) |
| SI (1) | SI2861223T1 (enExample) |
| SM (1) | SMT202200436T1 (enExample) |
| TW (3) | TWI590820B (enExample) |
| WO (1) | WO2013188847A1 (enExample) |
| ZA (1) | ZA201500288B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| SG11201701995PA (en) | 2014-09-18 | 2017-04-27 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| JP6720301B2 (ja) * | 2015-07-15 | 2020-07-08 | テラネクス | 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をｉｎ ｖｉｖｏで増強する方法 |
| US12337063B2 (en) * | 2016-09-02 | 2025-06-24 | University Of Sharjah | Formulation for atropine sulfate rapidly-disintegrating sublingual tablets |
| CA3069699A1 (en) * | 2017-07-13 | 2019-01-17 | Tonix Pharmaceuticals Holding Corp. | Analogs of cyclobenzaprine and amitryptilene |
| CN107519142B (zh) * | 2017-08-24 | 2021-02-26 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下片及其制备方法 |
| CN107496355B (zh) * | 2017-08-24 | 2021-04-30 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下喷雾剂及其制备方法 |
| BR112020004035A2 (pt) * | 2017-12-08 | 2020-09-01 | F. Hoffmann-La Roche Ag | formulação farmacêutica |
| AU2018383098B2 (en) | 2017-12-11 | 2024-12-12 | Tonix Pharma Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| CN108721240A (zh) * | 2018-06-08 | 2018-11-02 | 华益药业科技(安徽)有限公司 | 一种25mg阿米替林薄膜包衣片处方和工艺规程 |
| CA3109258A1 (en) | 2018-08-20 | 2020-02-27 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
| CA3156118A1 (en) * | 2019-09-30 | 2021-04-08 | Cadila Healthcare Limited | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CYCLOBENZAPRINE |
| CA3179754A1 (en) | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| US20240009146A1 (en) * | 2020-11-20 | 2024-01-11 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for alcohol use disorder |
| AU2021396509A1 (en) | 2020-12-07 | 2023-06-29 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for fibromyalgia |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| EP4412602A1 (en) | 2021-10-06 | 2024-08-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| WO2023250036A1 (en) | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc) |
| JP2025067457A (ja) * | 2023-10-13 | 2025-04-24 | 株式会社島津製作所 | 液体クロマトグラフにおけるコストパフォーマンスの算出方法、プログラム、および、解析装置 |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| AU3885799A (en) * | 1998-05-14 | 1999-11-29 | Alza Corporation | Antidepressant therapy |
| BR0013122A (pt) | 1999-08-13 | 2002-04-30 | Vela Pharmaceuticals Inc | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina |
| DE60021266T2 (de) | 1999-08-13 | 2006-05-24 | L&L Technologies, Llc | Verwendungen von Zusammensetzungen zur Behandlung oder Vorbeugung von Schlafstörungen unter Verwendung von sehr niedrigen Dosen von Cyclobenzaprin |
| AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
| WO2004071491A1 (en) * | 2003-02-04 | 2004-08-26 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
| US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| JP2009079060A (ja) * | 2008-10-15 | 2009-04-16 | Novadel Pharma Inc | 極性または非極性の、バッカルスプレーまたはカプセル |
| US20100266682A1 (en) * | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) * | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| NZ747040A (en) * | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
-
2013
- 2013-06-14 EP EP13804115.7A patent/EP2861223B1/en active Active
- 2013-06-14 SM SM20220436T patent/SMT202200436T1/it unknown
- 2013-06-14 PT PT138041157T patent/PT2861223T/pt unknown
- 2013-06-14 JP JP2015517469A patent/JP6259452B2/ja active Active
- 2013-06-14 TW TW102121267A patent/TWI590820B/zh active
- 2013-06-14 HU HUE13804115A patent/HUE060175T2/hu unknown
- 2013-06-14 RS RS20221005A patent/RS63822B1/sr unknown
- 2013-06-14 MY MYPI2014703784A patent/MY194495A/en unknown
- 2013-06-14 NZ NZ631144A patent/NZ631144A/en unknown
- 2013-06-14 AU AU2013274003A patent/AU2013274003B2/en active Active
- 2013-06-14 SG SG11201408318RA patent/SG11201408318RA/en unknown
- 2013-06-14 HR HRP20221325TT patent/HRP20221325T1/hr unknown
- 2013-06-14 CN CN202010024102.2A patent/CN111388430A/zh active Pending
- 2013-06-14 MX MX2014015436A patent/MX382516B/es unknown
- 2013-06-14 BR BR112014031394-6A patent/BR112014031394B1/pt active IP Right Grant
- 2013-06-14 CA CA3118913A patent/CA3118913C/en active Active
- 2013-06-14 CA CA2876902A patent/CA2876902C/en active Active
- 2013-06-14 LT LTEPPCT/US2013/046023T patent/LT2861223T/lt unknown
- 2013-06-14 SG SG10201605407TA patent/SG10201605407TA/en unknown
- 2013-06-14 TW TW106117185A patent/TWI642429B/zh active
- 2013-06-14 US US13/918,692 patent/US20140171515A1/en not_active Abandoned
- 2013-06-14 ES ES13804115T patent/ES2929133T3/es active Active
- 2013-06-14 AR ARP130102101A patent/AR092330A1/es not_active Application Discontinuation
- 2013-06-14 TW TW107117266A patent/TWI683660B/zh active
- 2013-06-14 PL PL13804115.7T patent/PL2861223T3/pl unknown
- 2013-06-14 NZ NZ726488A patent/NZ726488A/en unknown
- 2013-06-14 WO PCT/US2013/046023 patent/WO2013188847A1/en not_active Ceased
- 2013-06-14 DK DK13804115.7T patent/DK2861223T3/da active
- 2013-06-14 MX MX2021005317A patent/MX2021005317A/es unknown
- 2013-06-14 CN CN201380039522.6A patent/CN104684550A/zh active Pending
- 2013-06-14 SI SI201332010T patent/SI2861223T1/sl unknown
-
2014
- 2014-12-15 IL IL236268A patent/IL236268B/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00288A patent/ZA201500288B/en unknown
-
2017
- 2017-10-02 JP JP2017192713A patent/JP2017222726A/ja not_active Withdrawn
-
2018
- 2018-10-04 AU AU2018241128A patent/AU2018241128B2/en active Active
-
2019
- 2019-05-14 JP JP2019091262A patent/JP2019123757A/ja not_active Withdrawn
-
2021
- 2021-06-16 JP JP2021100154A patent/JP2021138765A/ja not_active Withdrawn
-
2024
- 2024-02-02 JP JP2024014696A patent/JP2024032964A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010121827A (ru) | Композиции для лечения болезни паркинсона | |
| US20220071929A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP6234899B2 (ja) | 喘息及びアレルギー性鼻炎の治療におけるアルギナーゼ阻害剤の使用 | |
| TW200838545A (en) | Therapeutic agent for painful disease | |
| JP2020505407A5 (enExample) | ||
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| HRP20240034T1 (hr) | Liječenje kardiovaskularnih bolesti | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP5902628B2 (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| JP2017503852A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2021525729A5 (enExample) | ||
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| EP4700016A3 (en) | Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof | |
| JP2016505050A5 (enExample) | ||
| JP2015521647A5 (enExample) | ||
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2011500731A5 (enExample) | ||
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| EP3493849B1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| NZ597359A (en) | Emergency interventions of active charcoal with dabigatran etexilate overdosing | |
| CN105451749B (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 |